(Q45152025)

English

Efficacy and acceptability of the fixed fluticasone + salmeterol combination in the treatment of acute asthma attacks. Results of a one-year comparative study

scientific article published in September 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Efficacy and acceptability of the fixed fluticasone + salmeterol combination in the treatment of acute asthma attacks. Results of a one-year comparative study (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1 reference

based on heuristic

inferred from title

author name string

A-B Tonnel

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

J-L Desfougères

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

language of work or name

0 references

publication date

1 September 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Revue de pneumologie clinique

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

60

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

209-216

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8417%2804%2972101-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8417%2804%2972101-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Salmeterol/Fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8417%2804%2972101-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8417%2804%2972101-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8417%2804%2972101-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patien

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8417%2804%2972101-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Trials to assess equivalence: the importance of rigorous methods

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8417%2804%2972101-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8417%2804%2972101-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8417%2804%2972101-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychological disorder in asthma is associated with poor control and poor adherence to inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8417%2804%2972101-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0761-8417(04)72101-X

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45152025&oldid=2118786153"